3SBio (HK:1530) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
3SBio Inc.’s subsidiary, Shenyang Sunshine Pharmaceutical, has secured exclusive commercialization rights for clifutinib besylate in Mainland China through a collaboration with Sunshine Lake Pharma. The agreement involves initial and milestone payments, while Sunshine Lake Pharma will manage the drug’s research, development, and production. Investors are advised to remain cautious regarding the potential success of clifutinib’s commercialization.
For further insights into HK:1530 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue